Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Immunobiologicals in Psoriasis at HUOL, UFRN, Natal, RN

Immunobiologicals in Psoriasis at HUOL, UFRN, Natal, RN

Pachêco, Arnóbio

Paperback

Medical Reference

ISBN10: 620782122X
ISBN13: 9786207821228
Publisher: Our Knowledge Publishing
Published: May 27 2025
Pages: 56
Weight: 0.19
Height: 0.13 Width: 6.00 Depth: 9.00
Language: English
Psoriasis is a chronic, immune-mediated, multifactorial inflammatory disease that may be associated with comorbidities and interfere with quality of life. The patients included in the study were treated with immunobiological agents from March 2008 to March 2015. Of the patients studied, 17 started treatment with Adalimumab, 15 with Infliximab, and 5 with Etanercept. The results showed that 37 patients (60.7%) controlled their psoriasis with a single immunobiological agent; 15 patients (24.6%) with a second immunobiological agent; 6 patients (9.8%) with a third immunobiological agent; and only 3 patients (4.9%) needed to use a fourth immunobiological agent, Ustekinumab, to achieve an effective therapeutic response. Immunobiologicals represent an important therapeutic resource for severe forms of psoriasis. In conclusion, excellent therapeutic results were observed in all patients, with few adverse effects and a high rate of adherence to treatment, providing them with personal rehabilitation and family, social, and professional reintegration.

Also from

Pachêco, Arnóbio

View All

Also in

Medical Reference

View All